Autoimmune diseases occur due to an overly active immune response, largely driven by dysregulated B cells and plasma cells. Given the key role that B cells and plasma cells play in autoimmune disease manifestations pathogenesis, they are prime targets for T cell engagers (TCEs). TCEs are an innovative class of therapeutics that direct T cells to eliminate disease-causing cells, including B cells and autoantibody-producing plasma cells.
Therapies that successfully and durably deplete B cells and plasma cells have the potential to provide meaningful benefits for patients, by not only addressing symptoms, but also directly addressing the cause of the disease itself. By harnessing the power of the immune system through direct engagement with T cells, TCEs have the potential to be a precise and effective treatment option in autoimmune diseases.
B Cells
Autoreactive B cells are key drivers of pathogenic processes in certain autoimmune diseases. Broad B cell depletion, which can be achieved through targeting CD19 , has the potential to affect an immune system reset in people with autoimmune diseases.
Plasma Cells
Autoantibody-producing plasma cells are central drivers of pathogenic processes in certain auto-immune diseases. Targeting BCMA may enable depletion of the autoantibodies that are central to the pathogenesis of some autoimmune diseases.
